Skip to main content

Table 4 Acetaminophen Requirement in Patients Suffering with COVID-19

From: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial

Dose of Acetaminophen HCQ / placebo HCQ / Levamisole Total
N (%) N (%) N (%)
Yes 12 (48.0) 10 (40.0) 22 (44.0)
500 mg tds for 2 days 1 (4.0) 0 (0.0) 1 (2.0)
500 mg tds for 3 days 3 (12.0) 8 (32.0) 11 (22.0)
500 mg tds for 8 days 1 (4.0) 0 (0.0) 1 (2.0)
500 mg tds for 10 days 1 (4.0) 0 (0.0) 1 (2.0)
500 mg tds for a week 5 (20.0) 2 (8.0) 7 (14.0)
500 mg tds for 2 weeks 1 (4.0) 0 (0.0) 1 (2.0)
No 13 (52.0) 15 (60.0) 28 (56.0)